Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction
J&J tends to be a cautious player when it comes to projecting peak sales for a top drug prospect. But its partners at Genmab clearly believe that the sky’s the limit on their myeloma drug Darzalex (daratumumab).
Initially pushed back to the last line of defense after multiple drug failures, the FDA approved several combinations using Darzalex as a second-line therapy late last year. And Genmab CEO Jan van de Winkel expects to see its end of the deal swell into the billions as more studies help expand the market for their partnered therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
